- To develop a miniaturized implant including: a cell chamber, a frame of biocompatible plastic optics and a membrane with a defined pore size designed for optimal protein therapeutic delivery.
- To develop stable therapeutic cell lines having the interferon transgene under the control of a synthetic optogenetic pathway.
- To develop a miniaturized wireless powered NIR light source.
- To develop suitable in-silico modelling tools to assist in the therapeutic cell line development considering the optogenetic pathway activation and IFN-ß delivery.
- To develop an industrial micro-injection moulding process for manufacturing the minimally invasive implant.
- To validate suitable sterilization protocols for the implant.
- To prove biocompatibility and therapeutical efficiency of the new implant by in vitro and in vivo
Optogenerapy project aims to develop and demonstrate a new optogenetics implant for controlled beta interferon (IFN-ß) protein delivery for treating Multiple Sclerosis patients.
The implementation of electronic systems in the human body has led to numerous medical progresses, but cell therapy-based clinical trials have shown serious adversities such as tumour formation and the transmission of infectious agents. The Optogenerapy project addresses this urgent clinical need for safe cell-based protein delivery therapies and applies the results for improving the quality of life of patients suffering from Multiple Sclerosis.
- To prove a health gain due to continuous low dose drug delivery that will prevent relapses and will delay disease progression into neurological decline stages.
- To define a clear regulatory path as a combined advanced-therapy medicine.